MedTrace Logo

Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients

NCT03273608 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2017-09-06

No results posted yet for this study

Summary

The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence in HCC management to physicians in the region, and to support the application of deTACE in treating advanced HCC patients.

Conditions

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Tri-Service General Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    lead OTHER_GOV

Principal Investigators

  • Yi-Hsiang Huang, M.D. Ph.D. · Taipei Veterans General Hospital, Taiwan

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-14
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03273608 on ClinicalTrials.gov